Dutch startup Cyclomics raised €2.6 million to move its Epinn methylation‑based cancer test and CyclomicsSeq assays toward CE‑IVD and eventual FDA clearance, aiming to commercialize its blood‑based methylation classification platform and nanopore‑enabled assays. The funding supports product definition and regulatory strategy for European and US markets. Boston‑area liquid biopsy firm Precede Biosciences closed an $83.5 million Series B and a $20 million credit facility to scale a transcriptome‑based liquid biopsy platform and deepen pharma partnerships. Precede said it is already collaborating with about 30 drug programs and will expand capacity to meet growing demand from oncology developers. Together these financings indicate investor appetite for diagnostics that pair molecular readouts with ML to support drug development and clinical decision making.